UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.    )

Filed by the Registrant  x                            Filed by a Party other than the Registrant  ¨

Check the appropriate box:

Cardiovascular/Metabolic

• Maximize value of current products

Bystolic

Phase IV Support

• 11 Phase IV Studies

• +3,700 patients

• Over 600 sites

Life Cycle

• FDC nebivolol/valsartan

• Phase III ongoing

• Filing in FY2014

• Expand pipeline

- Azimilide (Antiarrhythmic in patients with ICD – Phase III)

- TTP-399 (Glucokinase inhibitor in diabetes – Phase II)

Gavin Corcoran, MD

Executive Vice President

Research & Development,

Early and Clinical Development

Forest Research Institute, Inc.

Cardiovascular Bystolic nebivolol/ valsartan azimilide TTP-399

CNS Viibryd Namenda Namenda XR cariprazine levomilnacipran

Pain Savella GRT-6005

GI linaclotide

Respiratory Daliresp aclidinium aclidinium/ formoterol

Anti-lnfectives Teflaro ceftaroline/ avibactam ceftazidime/ avibactam BC3781

Mood Disorders Psychosis

Anxiety Depression Severe Depression Bipolar Depression Mania Schizophrenia

Serotonin 5HT Norepinephrine Dopamine

(SSRI & 5HT1a) Levomilnacipran (SNRI) Cariprazine (D2/D3 partial agonist)

ViibrydTM (vilazadone)

• SSRI with 5HT1a partial agonism

• Indicated for MDD

• Ongoing program to further define the utility of this drug for patients

- Low dose

- Relapse prevention

- Pediatrics

- General Anxiety Disorder

Levomilnacipran Pharmacology

• A new SNRI for the treatment of MDD

- Greater selectivity for the NE transporter

- More balanced increase in 5HT and NE in the brain

• Relief of symptoms of depression

• Potential for a positive effect on patient functionality

Levomilnacipran

Effect on Symptoms and Function

• Three pivotal trials examining doses from 40-120mg/day

- MADRS change from baseline

- SDS change from baseline

• Significant effect on both scores

MD-01

MADRS LSMD (Placebo-Adjusted)

0

-1

-2

-4

-5

-6

-7

* ** ***

*P<0.05, **P<0.01, ***P<0.001 versus placebo

40mg 80mg 120mg

Levomilnacipran

Effect on Symptoms and Function

• Three pivotal trials examining doses from 40-120mg/day

- MADRS change from baseline

- SDS change from baseline

• Significant effect on both scores

• Dose response in study with all 3 doses (MD-01)

• Lower rate of common adverse effects than most other SNRI

• Slight, non dose-dependent increase in HR/BP

Figure 3. Sheehan Disability Scale: Least Squares Mean Change From Baseline to Week 8 (ITT Population, MMRM)

A. Total Score B. Work Item Social Life Item Family Life Item

0 -1 -2 -3 -4 -5 -6 -7 -8 -9 -10

0 -1 -2 -3 -4 -5

LS Mean Change From Baseline

Placebo

Levomilnacipran SD, 40 mg/day

Levomilnacipran SD, 80 mg/day

Levomilnacipran SD, 120 mg/day

*P<05 and **P<01 vs placebo

Cariprazine Pharmacology

• Dopamine receptor partial agonist

- D3 preferring, but partial agonist of D2 and D3 receptors

- Less effect on histamine, adrenergic and 5HT2c

• Suitable for the treatment of a range of conditions

• Initial development for 2 indications

- Schizophrenia and acute mania

• 3 positive trials in each indication

- Dose range from 1.5-12mg

Significant Effect in Schizophrenia

Comparative Results for Schizophrenia (PANSS)

Mean change from baseline

RGH-MD-16 RGH-MD-04 RGH-MD-05

0 -5 Placebo -10 CAR 1.5 -15 CAR 3 -20 CAR 4.5 RIS 4

0 -5 Placebo -10 -15 CAR 3 -20 ARI 10 CAR 6 -25 -30

0 -5 Placebo -10 -15 CAR 3-6 CAR 6-9 -25 -30

0 1 2 3 4 5 6 0 1 2 3 4 5 6 0 1 2 3 4 5 6

Improvement in all active arms at week 6 were highly significant compared to placebo

Significant Effect in Acute Mania

Comparative Results for Mania (YMRS)

Mean change from baseline

RGH-MD-31 RGH-MD-32 RGH-MD-33

0 -5 Placebo -10 CAR 3-12 -15 -20

0 -5 -10 Placebo -15 CAR 3-12

0 -5 Placebo -10 CAR 6-12 CAR 3-6 -20

0 3 6 9 12 15 18 21 0 3 6 9 12 15 18 21 0 3 6 9 12 15 18 21

Improvement in all active arms at week 3 were highly significant compared to placebo

Favorable Adverse Event Profile

• Most common adverse effects

- Insomnia, headache, constipation

• Low potential for

- Clinically relevant weight gain, somnolence and EPS/EPD

• Few changes on metabolic parameters

- Liver enzymes, blood lipids, prolactin, CPK

• Akathisia

- Up to 14% in schizophrenia and 20% in acute mania

- Most cases were mild to moderate

- <2% of patients withdrew from studies for akathisia

Focus on Pain

• Savella

- Indicated for the treatment of fibromyalgia

• GRT6005

- Novel opioid for chronic pain

- Potent activity through the mu and OLR-1 receptors

- Currently in Phase II

• Osteoarthritis, neuropathic pain, low back pain

• Cancer pain (ex-US)

Linaclotide

• Ongoing unmet need

- IBS-C

- Chronic constipation

• Conditions characterized by

- Bowel symptoms

• Constipation

- Abdominal symptoms

• Bloating, discomfort

linaclotide

Lumen

Cl

HCO3

Na

H2O

GC-C

CFTR

P

GTP

cGMP

PKGII

Serosa

Afferent

pain fibers

Linaclotide Pivotal Data

• Phase III

- 2 large studies in CC and 2 in IBS-c

- 2 long term studies

• Endpoints focused on demonstrating effect on bowel and abdominal symptoms

- Significant effect on all primary and secondary parameters

- Relief noted within a week of therapy

Randomized Withdrawal

CC Patients

Stool Frequency (CSBM)

CSBMs 0 1 2 3

Treatment Period

RW Period

BL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Trial Week

Treatment Period

290 µg

Placebo

IBS-C Patients

Stool Frequency (CSBM)

Treatment Period

RW Period

CSBMs 0 1 2 3

BL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Trial Week

Treatment Period

290 µg

Placebo

Linaclotide Phase III IBS-C Trial

Weekly Change in Abdominal Symptoms

Treatment Groups

266 µg

Placebo

Discomfort

% Change

0 -10 -20 -30 -40 -50 -60

BL 2 4 6 8 10 12 14 16 18 20 22 24 26

Trial Week

Bloating

% Change

0 -10 -20 -30 -40 -50 -60

BL 2 4 6 8 10 12 14 16 18 20 22 24 26

Trial Week

Fullness

% Change

0 -10 -20 -30 -40 -50 -60

BL 2 4 6 8 10 12 14 16 18 20 22 24 26

Trial Week

Cramping

% Change

0 -10 -20 -30 -40 -50 -60

BL 2 4 6 8 10 12 14 16 18 20 22 24 26

Trial Week

p <0.01 for each of the 26 Weeks in the Treatment Period. Patients with main baseline score ³ 3 for each respective parameter.

Cardiovascular

CNS

Pain

GI

Respiratory

Anti-Infectives

Bystolic

nebivolol/

valsartan

azimilide

TTP-399

Viibryd

Namenda

Namenda XR cariprazine levomilnacipran

Savella

GRT-6005

linaclotide

Daliresp

aclidinium

aclidinium/

formoterol

Teflaro

ceftaroline/

avibactam

ceftazidime/

avibactam

BC3781

• Robust pipeline of important medicines in these 3 therapeutic areas

Cardiovascular

CNS

Pain

GI

Respiratory

Anti-Infectives

Bystolic

nebivolol/

valsartan

azimilide

TTP-399

Viibryd

Namenda Namenda XR

cariprazine levomilnacipran

Savella

GRT-6005

linaclotide

Daliresp

aclidinium

aclidinium/

formoterol

Teflaro

ceftaroline/

avibactam

ceftazidime/

avibactam

BC3781

• Scientific programs that develop useful data for patients and physicians beyond required registration studies

Cardiovascular

CNS

Pain

GI

Respiratory

Anti-Infectives

Bystolic

nebivolol/

valsartan

azimilide

TTP-399

Viibryd

Namenda

Namenda XR cariprazine levomilnacipran

Savella

GRT-6005

linaclotide

Daliresp

aclidinium

aclidinium/

formoterol

Teflaro

ceftaroline/

avibactam

ceftazidime/

avibactam

BC3781

• Our therapeutic focus of complimentary medicines demonstrates our commitment to change the lives of patients with significant diseases

Building the Future

A Focus on Our Products & Therapeutic Categories

Forest Laboratories, Inc.

Harry J. Sacks, MD, FAAP

Executive Director,

Clinical Development – Respiratory Forest Research Institute, Inc.

Cardiovascular CNS Pain GI Respiratory Anti-lnfectives

Bystolic

nebivolol/

valsartan

azimilide

TTP-399 Viibryd

Namenda

NamendaXR

cariprazine

levomilnacipran Savella

GRT-6005 linaclotide Daliresp

aclidinium

aclidinium/ formoterol Teflaro

ceftaroline/

avibactam

ceftazidime/

avibactam

BC3781

Improve lives of

PATIENTS WITH RESPIRATORY DISEASES

Forest Laboratories, Inc.

Respiratory Overview

Goal: Improve lives of patients with respiratory diseases

• Robust COPD development programs underway

• Product differentiation studies for all products

• Investigate products in other respiratory conditions such as asthma

• Seek out and invest in new treatments

Managing the Spectrum of COPD

Forest Laboratories, Inc.

Managing the Spectrum of COPD

• Affects as many as 24 million Americans1

• Third leading cause of death in US2

• Breathlessness is leading symptom

aclidinium / formoterol

aclidinium Daliresp

MILD MODERATE SEVERE VERY SEVERE

Source: 1 COPD Foundation Website: http://www.copdfoundation.org/COPDYOU/AboutCOPD.aspx, accessed June 18, 2012

2Centers for Disease Control (CDC) and Prevention’s National Center for Health Statistics (NCHS), Deaths: Preliminary Data for 2008. http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_02.pdf. Accessed 6/18/2012.

Aclidinium Bromide: A Novel Anticholinergic Bronchodilator

Efficacy

Improved lung function 24 hour control Symptom relief

Safety

Well tolerated Low drug interaction

Successful FDA AdCom

Inhaler

Simple to use Patient friendly

COPD

TREATMENT OPTIONS

Forest Laboratories, Inc.

Aclidinium Bromide: A Novel Anticholinergic Bronchodilator

400

350 300 250 200

150 100

50

0

-50

-100

0

Evening administration

Aclidinium 400 ug * BID (N=29)

Tiotropium 18 ug QD (N=28)

Placebo

(N=30)

0 1 2 4 5 6 7 8 10 11 12 13 14 16 17 18 19 20 22 23 24

Time, h

Study LAS-MD-23; presented at Feb. 23, 2012 FDA Advisory Committee

Further Studies

Planned

Forest Laboratories, Inc.

Further Studies Planned

• Relative effect of aclidinium over 24 hours

- Direct comparison to approved product

• Exacerbations

- Confirm aclidinium reduces flare ups

• Exercise Tolerance

- Confirm aclidinium enables patients to better tolerate physical exertion

Aclidinium + Formoterol FDC

Forest Laboratories, Inc.

Aclidinium + Formoterol FDC

• Phase III pivotal studies currently enrolling

• For moderate to severe patients requiring more symptom control than with a single agent

- Step between monotherapy and inhaled steroids

- May delay need for steroids

• Established efficacy in Phase II; well tolerated

• NDA – Early CY 2014

Importance of Reducing COPD Exacerbations

• History of exacerbations predicts higher likelihood of future exacerbations

• Reduction of exacerbations is a key component of COPD management1

• Exacerbations are associated with accelerated deterioration in lung function and increased risk of death

• Daliresp reduces the rate of exacerbations

Reference: 1Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease, Revised 2011, http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf, Accessed 6/18/2011.

Daliresp (roflumilast, 500 mcg tablets)

Severe and Very Severe COPD

“DALIRESP is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations”

• Approved February 2011

- Once daily oral treatment

- First and only approved phosphodiesterase 4 (PDE-4) inhibitor

- First new drug class in over 25 years for COPD treatment

• Place in treatment: Severe COPD with a history of exacerbations in addition to bronchodilator therapy

Cardiovascular CNS Pain GI Respiratory Anti-Infectives

Bystolic

nebivolol/

valsartan

azimilide

TTP-399 Namenda

NamendaXR

cariprazine

levomilnacipran Savella GRT-6005 linaclotide Daliresp

aclidinium

aclidinium/ formoterol Teflaro

ceftaroline/

avibactam

ceftazidime/

avibactam

BC3781

Building the Future

A Focus on Our Products & Therapeutic Categories

Forest Laboratories, Inc.

Paul C. Grint, MD

President, Cerexa, Inc.

Cardiovascular CNS Pain GI Respiratory Anti-Infectives

Bystolic

nebivolol/

valsartan

azimilide

TTP-399 Namenda Namenda XR

cariprazine

levomilnacipran Savella GRT-6005 linaclotide Daliresp

aclidinium

aclidinium/ formoterol Teflaro

ceftaroline/

avibactam

ceftazidime/

avibactam

BC3781

Bad Bugs Need Drugs

• Antibiotic resistant infections in the US

- 8 million hospital days

- $20B annual cost Public health threat

• National security threat

• The 10 x '20 Initiative • NewDrugs4BadBugs

- European initiative against antimicrobial resistance

• GAIN Legislation - Generate Antibiotic Incentives Now

Bad Bugs

Need Drugs

10x ‘20

Ten new ANTIBIOTICS by 2020

10

9

8

7

6

5

4

3

2

1 ceftaroline fosamil: Forest Laboratories, Inc.

Approved October 29, 2010

We could potentially deliver an additional 2 to 3 of these 10

Spectrum of Activity

Resistant Gram+

Gram+

Gram–

Resistant Gram–

Teflaro

ceftaroline + avibactam

ceftazidime + avibactam

MRSA

MDRSP

S. pneumoniae

S. aureus

H. influenzae

E. coli

K. pneumoniae

ESBL

producing Gram–

P. aeruginosa

Nabriva BC-3781

Ceftaroline Life Cycle Studies

patch®

pediatric antibiotic therapy

with ceftaroline in the hospital

• Pediatric PK studies including premature newborns

• Comparative studies in children

- Community acquired bacterial pneumonia

- Complicated skin infections

- CABP at risk of MRSA

• Study designs for additional infections being evaluated

AWARE: Assessing Worldwide Antimicrobial Resistance Evaluation

• In Vitro US Surveillance Program

• No trend of reduced susceptibility to ceftaroline for pathogens tested between 2008 and 2011

• Expanding program

- 70 centers in 2011

- 200 centers in 2012

% Susceptible to ceftaroline (FDA Breakpoints)

Pathogen 2008 2009 2010 2011

S. aureus 97.0 98.4 99.2 99.0

S. pneumoniae 98.8 98.5 98.8 99.1

S. pyogenes 100.0 99.1 99.1 99.8

S. agalactiae 100.0 100.0 99.7 99.8

E. coli 90.1 84.9 84.9 83.1

K. pneumoniae 82.7 79.3 86.1 81.3

K. oxytoca 86.2 83.3 85.2 82.4

H. influenzae 100.0 100.0 99.7 99.6

Important Utility of ß-Lactam Antibiotics

• ß-Lactams have been effective life saving antibiotics for five decades

• ß-lactamases are threatening the utility of ß-Lactams

- ß-Lactamase-induced resistance is increasing worldwide

- No treatment available for new extended ß-lactamases

- Carbepenems are now threatened by KPC-producing organisms

Avibactam: Next Generation ß-Lactamase Inhibitor

• Non ß-lactam ß-lactamase inhibitor

- Does not bind to PBPs

- No intrinsic antibacterial activity

• Inhibits a broad spectrum of clinically important ß-lactamases

- Older inhibitors do not offer coverage of important enzymes such as KPC or AmpC

• Does NOT induce AmpC ß-lactamase

• PK profile compatible for combination with IV cephalosporins ceftazidime and ceftaroline

• Potential for combination with additional ß-lactam antibiotics

O

H2N

N

O

N

OSO3Na

Avibactam Combinations

Globally, over a million patients a year suffer from infections known or suspected to be resistant to cephalosporins, and is expected to grow by more than 25% over the next decade

• Ceftazidime Avibactam

- Phase III program to treat serious Gram-negative bacterial infections has been initiated

• Complicated Intra-Abdominal Infections (cIAI)

• Complicated Urinary Tract Infections (cUTI)

• Ceftaroline Avibactam

- Phase II program completing

- Planning Phase III study designs

BC-3781 Nabriva Therapeutics

• Novel class of antibiotics, the pleuromutilins

- Active against a wide range of Gram-positive pathogens as well as certain Gram-negative organisms

• No cross resistance

• Low propensity for inducing resistance itself

• Developed both intravenous and oral forms to treat patients after they are discharged from a hospital

• Positive Phase II study results in 207 patients with ABSSSI

We expect to advance BC-3781 into pivotal Phase III studies in 2013

Summary

• Very significant antibiotic portfolio that covers a wide spectrum of Gram-positive and Gram-negative pathogens

• Urgent medical need for new antibiotic development

• Potential to deliver an additional 2 to 3 antibiotics for the IDSA 10 x ‘20 Initiative

Bad Bugs Need Drugs

10x ‘20

Ten new ANTIBIOTICS by 2020

Building the Future

A Focus on Our Products & Therapeutic Categories

Forest Laboratories, Inc.

A Focus On Our Commercial Philosophy & Therapeutic Areas

Forest Laboratories, Inc.

Forest’s Rich Commercial History

Past 15 Years

• Total revenue from $300MM to $4B

• 14 launches

- 14 products

- 17 indications

Significant Product Launches

Celexa

citalopram HBr

Benicar TABLETS

Lexapro

Bystolic

Namenda

“The Forest Way”

Ability to right-size and deploy commercial effort to create value

Commercial Operations

Forest Laboratories, Inc.

Commercial Operations 2012

ELAINE HOCHBERG

Executive Vice President & Chief Commercial Officer

Global Commercial & U.S. Marketing

Office Based Sales

Managed Markets, Government & Policy

Product Management

Global Commercialization

Marketing Services

Digital Marketing & Marketing Communications

4 Primary Care Sales Forces

2 Speciality Sales Forces

Institutional Sales

Hospital & LTC Sales Force

National / Regional Account Managers

Government Sales & Long Term Care Account Managers Trade Sales

Wholesaler & Retail Chain Account Managers

Global Market Research

Marketing Practices & Production

Contract Sales Organization

Contract Sales Organization

Public Policy & Government Affairs

Global Commercial Assessments

Sales Administration & Sales Training

Forest’s Advantage: Field Force Strength

RANKED 1st on Selling Power magazine’s

“50 Best Companies to Sell For”

in 20111

We Target per Year:

• ~ 250,000 physicians

• ~ 3,000 hospitals and clinics

• ~ 500 senior care pharmacies

Productivity2

1st Forest

2nd AstraZeneca

3rd Pfizer

4th Takeda

5th Novartis

6th GSK

7th Lilly

8th Merck

9th Boehringer I.

10th Abbott

Call Quality3

1st Pfizer

2nd Lilly

3rd Abbott

4th Boehringer I.

5th Novartis

6th Forest

7th Takeda

8th Merck

9th AstraZeneca

10th GSK

12011 survey by Selling Power magazine.

2Productivity measures in terms of calls per sales representation.

Companies were assessed if ranked within the top 10 based on total number of Calls

3Source of Calls: IMS IPS, 12 months ending January 2012;

Source for sales reps: SDI’s Sales Force Structure & Strategies Report 4Q 2011 (includes contract and part-time reps)

Forest rep count used to calculation is internal data and not based on SDI’s report

Call Quality measured as Minutes per Detail (sample drops are excluded)

Companies were assessed if ranked within the top 10 based on total number of Details

Forest Reps Consistently Reach More Than 80% of Primary Care Physicians*

More Than Twice Per Month

Reach

90%

85%

80%

75%

70%

65%

60%

Reach and Frequency to 98,000 Decile 3–10 PCP’s

Reach Call Frequency

81.2% 82.5% 81.8% 83.7%

2.55 2.55 2.65 2.78

2008 2009 2010 2011

3.2

3.1

2.9

2.8

2.7

2.5

2.4

2.3

2.1

2.0

Monthly Call Frequency

*98,000 (Decile 3–10) Primary Care Physicians Internal Call Data

Forest Position with PCPs is Strong and Growing Stronger

Company Details – Primary Care Physicians

Details (thousands)

5,000

4,000

3,000

2,000

1,000

0

CY2007

CY2008 CY2009

Forest Merck

AstraZeneca Lilly

Novartis Takeda

Abbott Sanofi Aventis

CY2010

Pfizer

GSK

Boehringer

CY2011

Source: IMS IPS, Office-based Details

Building the Future

A Focus On Our Products

& Therapeutic Categories

Forest Laboratories, Inc.

William Meury

Senior Vice President,

Global Commercial & US Marketing

Forest Laboratories, Inc.

Building the Future

A Focus on Our Products

& Therapeutic Categories

Forest Laboratories, Inc.

Cardiovascular

Bystolic

nebivolol/

valsartan

Azimilide

TTP-399 CNS

Viibryd Namenda

Namenda

XR cariprazine levomilnacipran pain Savella GRT-6005 GI linaclotide Respiratory Daliresp aclidinium aclidinium/ formoterol Anti-Infectives Teflaro ceftaroline/avibactam ceftazidime/avibactam BC3781

User Trends and Prescriptions

Are Strong

Cumulative Bystolic Prescribers

300,000 225,000 150,000, 75,000,

0

264,057

1/4/08

10/9/09

6/13/08

11/21/08

5/1/09

3/19/10

8/27/10

2/4/11

7/15/11

12/23/11

5/25/12

Over 5 Million Prescriptions

Prescriptions up 20% in 1st calendar quarter vs. prior year

550 530 510 490 470 450 430 410 390 370 350

Apr -11 May-11 June-11 Aug-11 Sep-11 Oct-11 Nov-11, Dec-11Jan-12 Feb-12 Mar-12 Apr-12 May 12

IMS NGps & IMS Xponent, updated through May 2012

Market for 1st /2nd Line is Larger

Patients receiving 3 or 4 anti-hypertensives of control BP

Position Bystolic Here!

26% 74%

Patients received 1 or 2 anti-hypertensives to control BP

Sources: Decision Resources (Pharamacor 2009); IMS/SDI (Custom) Hypertension Monthly Report, January 2012.

Bystolic is Being Used 1st or 2nd Line

Bystolic Line of Therapy

Difference in 1st and 2nd Line

4th Line 15%

3rd Line 27%

1st & 2nd Line 58%

Bystolic 4%

-1%

5% 4% 3% 2% 0% (1%) (2%)

Beta Blocker Market

Source: IMS Study Drug Order as Written, First Filled

11 Bystolic Clinical Studies

Over 4 Years

Study

Conclusion

9

10

11

Weiss/Greathouse

Lacourciere

Weiss

Neutel

Lacourciere

Weber

Saunders

Punzi

Registration

Registration

Lukic

Monotherapy

Monotherapy

Monotherapy Stage 2

Add on to ACE, ARB, HCTZ

Initial combination with ACE

Black patients

Hispanic patients

Younger and Older (+65)

Male and Female

<55 Years of Age Monotherapy

Cardiovascular

Bystolic

nebivolo

valsartan

azimilide

TTP-399

CNS

Viibryd

Namenda

Namenda XR

cariprazine

levomilnacipran

Pain

Savella

GRT-6005

GI

linaclotied

Respiratory

Daliresp

aclidinium

aclidinium/formoterol

Anti-Infectives

Teflaro

ceftaroline/

avibactam

ceftazidime/avibactam

BC3781

Bystolic + valsartan

54.2MM Prescriptions

ARB + BB ARB + BB + HCT ARB + HCT

10MM Rx 15.9MM Rx 28.3MM Rx

$3.3B Annual Sales

Cardiovascular

Bystolic nebivolol/valsartan azimilide TTP-399

CNS

Viibryd Namenda Namenda XR cariprazine levomilnacipran

Pain

Savella

GRT-6005

GI

Linclotide

Respiratory

Daliresp

Aclidinium

Aclidinium/formoterol

Anti-Infectives

Teflaro

Ceftaroline/avibactam

Ceftazidime/avibactam

BC3781

Namenda

Large User Base

173,000

129,750

86,500

43,250

0

173,000

MD Users

High Satisfaction Rate

7.0

6.0

5.0

4.0

3.0

2.0

1.0

0

5.1

5.1

5.0

Basic ADLs

Cognitive Decline

Quality of Life

Source: IMS XPO & Market Research

Once-Daily

NamendaXR

(memantine HCL) extended release capsules

TM

Once-Daliy

Namenda XR

(Memantine HCI)extended release capsules

Demonstrated effective with all ACHEI

Improvement in cognition, function, and behavior

AE consistent with Namenda

Once a day high dose formulation

TM

Viibryd is off to a Strong Start

Prescriptions

Market Share %

0

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

0.45

0.50

Jul-11

Sep-11

Nov-11

Jan-12

Mar-12

TM

May-12

0

10

20

30

40

50

60

70

80

90

100

Total Prescription Volume (000s)

TRx

Mkt Share

Overall volume up 20% since start of 2012

Source: IMS NGPS NPA, May 2012

Viibryd Prescribers are on the Rise

Prescribers Since Launch

Prescribers Since Launch

60,000 45,000 30,000 15,000 0

6/17/11 7/29/11 9/9/11 10/21/11 12/2/11 1/13/12 2/24/12 4/6/12 5/18/12

1,000 added/week

50,516

Source: IMS Xponent, Week ending 5/18/2012

Viibryd is off to a Strong Start

Physician Reported Use of Viibryd

4+ Line 17% 3rd Line 28% 1st Line 29% 2nd Line 26%

Source: Market Research

TM

Viibryd TM

LEVOMILNACIPRAN

Forest Laboratories, Inc.

Levomilnacipran

Dual Reuptake Inhibitor for Major Depressive Disorder (MDD)

200 million prescriptions written

Sales for antidepressants approximately $18B

Only 30–40% of patients on any achieve remission

Source: STAR-D and GYK, 2008

Levomilnacipran

Dual Reuptake Inhibitor for Major Depression Disorder (MDD)

Strong effect on the MADRAS

Significant effect on function

Acceptable adverse event profile

Source: STAR D and GIK, 2008

Market Positions for Levomilnacipran

1st line

2nd line

3rd line

Treatment Resistant

SSRIs

SNRIs Wellbutrin

Anti-psychotics

Viibryd levomilnacipram

CARIPARAZINE

Forest Laboratories, Inc.

Cariprazine: A Novel Next Step

D2/5HT

Antagonists

D2 Partial

Agonist

New D3/D2

Partial Agonist

Risperdal

Zyprexa

Seroquel

Geodon

Clozaril

Invega

Saphris

Fanapt

Latuda

Abilify

Cariprazine

Recent Launch Performance

Total Rx (000s)

Latuda #10

Saphris #8

Fanapt #9

40

30

20

10

0

M1 M3 M5 M7 M9 M11 M13 M15 M17 M19 M21 M23

Source: IMS NPA TRx, March 2012

Bipolar Depression and MDD Markets

Abilify – $5.3B 22% 26% 39% 13% Source: IMS NSP, MAT April 2012; NDTI, MAT April 2012

Note: “Others” includes Psychoses unspecified, autism, anxiety, OCD, domestic

Schizophrenia

Bipolar Disorder

Depression

Others

Seroquel/XR – $5.5B

29% 17% 41% 14%

Cardiovascular

CNS

Pain

GI

Respiratory

Anti-Infectives

Bystolic

nebivolol/

valsartan

azimilide

TTP-399

Viibryd

Namenda

Namenda XR

cariprazine

levomilnacipran

Savella

GRT-6005

linaclotide

Daliresp

aclidinium

aclidinium/

formoterol

Teflaro

ceftaroline/

avibactam

ceftazidime/

avibactam

BC3781

CURRENT TREATMENTS

Forest Laboratories, Inc.

Linaclotide Provides Multi-symptom Relief

Linaclotide addresses constellation of symptoms in CC/IBSc

Relieve pain Relieve bloating and discomfort Improve bowel function

Two Important Sources of Business

Convert Rx and OTC markets

Prescription Market 24%

$2.2B

$7.0B

76% OTC Market (@ branded RX pricing)

Source: Market Research & IMS

Linaclotide for CC and IBSc

(MM)

CC

IBS-C

Total

Prevalence

26.0

13.2

39.2

Patients Seeking Care

7.9

7.6

15.5

Dissatisfied Patients (62-68%)

4.9

5.2

10.1

Satisfaction with current therapies is low

60-70% of patients seeking care are dissatisfied with current therapy

Lieborman Study, 2010

OTC Conversion Rates

40% 30% 20% 10% 0%

20% NSAIDs to Cox-2s

23% H2s to PPls

37% Sedating to Non-Sedating Antihistamines

Source: Kline OTC Sales Date

Linaclotide Post-launch

Promotional Effort

- +1,500 representatives

- 90,000 physicians

Major educational campaign directed to patients

Cardiovascular

Bystolic

Nebivolol/

Valsartan

Azimilide

TTP-399

CNS

Viibryd

Namenda

Namenda XR

Cariprazine

Levomilnacipran

Pain

Savella

GRT-6005

GI

Linaclotide

Respiratory

Daliresp

Aclidinium

Aclidinium/

Formoterol

Anti-infectives

Teflaro

Ceftaroline/

Avibactam

Ceftazidime/

Avibactam

BC3781

COPD Product Line

Aclildinium

LAMA

Acilidinium

/formoterol

LAMA/LABA

Daliresp

PDEIV Inhibitor

Efficacy

Moderate COPD

Severe COPD

Need for New Therapies

Patients are Still Experiencing Symptoms Despite Treatment

Overall PUD PCP

70% 53% 35% 18% 0% 55% 64% 46% 41% 52% 28%

Experiencing symptoms with monotherapy

Experiencing symptoms with combination Spiriva + ICS/LABA

Source: Forest Physician COPD Research GfK COPD Study, 2008

Percentage of Patients Requiring Treatment in the ED

30% 23% 15% 8% 0% 21% 27% 20%

AII MDs PUDs PCPs

Daliresp off to a Strong Start with Pulmonologists Overall volume up 42% since start of 2012

7,000 6,000 5,000 4,000 3,000 2,000 1,000 PUD Share 2.6% 2.1% 1.6% 1.1% 0.6% 0.1%-0.4%

PUD Market Share TRx

0 5/27/11 7/8/11 8/19/11 9/30/11 11/11/11 12/23/11 2/3/2012 3/16/12 4/27/12

Updated Weekly Data Week Ending May 2012

Daliresp off to a Strong Start

With Pulmonologists

Total PUD Users

5,000 3,750 2,500 1,250

0

504 1,070 1,580 1,990 2,369 2,715 3,033 3,306 3,577 3,811 4,031

Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May

Source: IMS Xponent, Week ending 5/25/2012

PCP DEVELOPMENT

Forest Laboratories, Inc.

PCP USAGE DOUBLES:

20,000 TO 40,000

Forest Laboratories,Inc.

44% Increase in Hospital

Using Daliresp

Hospitals Purchasing

1,800

1,575

1,350

1,125

900

675

450

225

0

1,198

+531 Hospitals

1,729

Before Hospital Launch

After Hospital Launch

Updated Weekly Data Week Ending May 11

ACLIDINIUM

Forest Laboratories, Inc.

Aclidinium

Long acting inhaled anti-cholinergic bronchodilator

Long residence time at M3 receptors and shorter residence time at the M2 receptors

Novel, multi-dose device, Genuair

Rapid effect on FEV1

Low incidence of side effects

Novel, easy to use inhaler

Aclidinium Promotional Effort

1,500 representatives

90,000 physicians

Sampling

Advertising

Peer to peer promotional programs

ACLIDINIUM-FORMOTEROL

Forest Laboratories, Inc.

Cardiovascular

Bystolic

Nebivolol/

Valsartan

Azimilide

TTP-399

CNS

Viibryd

Namenda

Namenda XR

Cariprazine

levomilnacipran

Pain

Savella

GRT-6005

GI

Linaclotide

Respiratory

Daliresp

aclidinium

aclidinium/

formoterol

Anti-infectives

Teflaro

ceftaroline/

avibactam

ceftazidime/

avibactam

BC3781

Teflaro

Purchasing Hospitals

Above Cubicin

Tygacil

Zyvox

TEFLARO

Doribax

Cubicin

Vibativ

Weekly Accounts Purchasing

1,500

1,125

750

375

0

W1

W6

W11

W16

W21

W26

W31

W36

W41

W46

W51

W56

W61

W66

W71

Weeks Post-Launch

IMS, Hospital Report, 2012

Teflaro

20,000

15,000

10,000

5,000

Weekly DOT

Days of Therapy

Above to Zyvox

0

W1

W6

W11

W16

W21

W26

W31

W36

W41

W46

W51

W56

W61

W66

W71

Tygacil

Cubicin

Doribax

TEFLARO

Zyvox

Vibativ

Weeks post-Launch

Ims, Hospital Report, 2012

Teflaro

Has Demonstrated High Efficacy Rates in CABP & ABSSSI

Day 4 CABP

TEFLARO 69.5% CABP

Ceftriaxone 59.4%

0% 20% 40% 60% 80% 100%

S. pneumoniae

100% 80% 60% 40% 20% 0%

85.7% 69.5%

TEFLARO Ceftriaxone

Day 3 ABSSSI

TEFLARO 74.0% ABSSSI

Vanco/Aztreonam 66.2%

0% 20% 40% 60% 80% 100%

MRSA 100% 80% 60% 40% 20% 0%

93.4% 94.3%

TEFLARO Vanco/Aztreonam

Usage Patterns

40% 25%

30% 33%

20%

10%

0%

Percentage of 1st line Use

Emergency Department Use

100% 88%

75%

50%

25%

0%

Satisfaction

Source: Market Research

Teflaro Prescribing Intentions are High

Future Prescribing Expectation IDs and Internists

100% 2% 5%

75%

50% 98% 95%

25%

0%

Plan to initiate use of Teflaro for cSSSI (n=43) Plan to initiate use of Teflaro for CABP (n=43)

Source: Market Research

Forest Antibiotic Franchise

First Line – Empiric Therapy

Teflaro

ceftaroline/avibactam

ceftazidime/avibactam

“Workhorse antibiotic”

for cSSSI and CAP

Ceftaroline with ESBL

Coverage will expand use

of ceftaroline for more

severe infections

Excellent activity against

Gram- pathogens such

as pseudomonas

Gram-negative U.S. Market Share

Days of Therapy (non-retail)

Carbapenems

14%

Cephalosporins

13%

IV Quinolones

34%

Piperacillin/tazobactam

39%

IV Quinolones

Piperacillin/tazobactam

Cephalosporins

Carbapenems

Data Source: IMS NSP Non-retail grams (MAT April 2012) converted to days of therapy using AMR grams/DOT (MAT June 2011)

Defined market includes:

Piperacillin/tazobactam; IV Quinolones; Ciprofloxacin iv, levofloxacin iv; carbapenems; meropenem; imipenem/cilastatin, doripenem; cephalosporins: cefepime and ceftazidime

Cardiovascular CNS Pain GI Respiratory Anti-Infectives

Bystolic nebivolol/valsartan azimilide TTP-399

Viibryd Namenda Namenda XR cariprazine levomilnacipran

Savella GRT-6005

Linaclotide

Daliresp aclidinium aclidinium/formoterol

Teflaro ceftaroline/avibactam ceftazidime/avibactam BC3781

Building the Future

A Focus on Our Products

&Therapeutic Categories

Forest Laboratories, Inc.